AstraZeneca Pharma India share news, announcements and annual reports
NSE: ASTRAZENBSE: 506820Pharmaceuticals & BiotechnologySmall Cap
AstraZeneca Pharma India Limited · Formerly Astra IDL · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1982 on BSE, May 2001 on NSE
Last close ₹6,291.50down ₹73.00 (1.15%)BSE ₹6,283.25
Share price at the NSE close on 2 Nov 2026. Previous close ₹6,364.50.
2 Nov: open ₹6,353.00, high ₹6,450.00, low ₹6,250.50
52-week range of traded prices to 2 Nov 2026
₹5,640.00Low, 9 Oct 2026₹9,849.50High, 3 Nov 2025
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,729 Cr333rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 92.73
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 18.02
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.57%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 24.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 7,49338.5% delivered
AstraZeneca Pharma India board meetings
121 filed, newest first. Page 2 of 3.
Apr 2017
Feb 2017
Jan 2017
Dec 2016
Oct 2016
Jul 2016
Apr 2016
Feb 2016
Jan 2016
Dec 2015
3 Dec · Board meeting
Nov 2015
Oct 2015
Jul 2015
May 2015
Jan 2015
Oct 2014
16 Oct · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2014. Further the 'Trading Window' shall remain closed for all Specified Persons, from October 16, 2014 to November 4, 2014 (both days inclusive) in terms of Company - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992.
Aug 2014
13 Aug · Board meeting
Board of Directors considered, inter alia, the following; 1. The Board noted and confirmed the appointment of Mr.Rajesh Marwaha as the Chief Financial Officer of the Company, effective August 04, 2014. 2. Approved the appointment of Mr. Anantha Murthy N as the Legal Counsel and Company Secretary and also designated him as the Compliance Officer of the Company. Prior to the above appointment he was the Legal Counsel and Associate Company Secretary.1 Aug · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2014. The 'Trading Window' shall remain closed for all Specified Persons, from August 1, 2014 to August 13, 2014 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Preventiion of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider trading) Regulations, 1992.
May 2014
30 May · Board meeting
In view of absence of profits for the year ended March 31, 2014, and to conserve resources for future growth, the Board has not recommended any dividend on equity shares for the Financial Year ended March 31, 2014.22 May · Board meeting
For considering Audited Financial Results of the Company, for the last quarter and financial year ended March 31, 2014 & may also consider 'recommendation of dividend' for the financial year ended March 31, 2014.5 May · Board meeting
Board of Directors of the Company at its meeting held on May 05, 2014, inter alia, has approved seeking approval of shareholders of the Company through Postal Ballot for the voluntary delisting of equity shares of the Company proposed by AstraZeneca Pharmaceuticals AB, Sweden, Promoter of the Company, in terms of Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009.2 May · Board meeting
To consider inter-alia seeking approval of shareholders of the Company through Postal Ballot, for the voluntary delisting proposed by AstraZeneca Pharmaceuticals AB Sweden, Promoter of the Company, in terms of Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009.
Apr 2014
15 Apr · Board meeting
Board of Directors of the Company at its meeting held on April 15, 2014, deferred consideration of seeking approval of shareholders of the Company through Postal Ballot for the delisting of equity shares of the Company proposed by the Promoters of the Company, in the light of discussions with ICICI Securities Limited, the Manager and Walker Chandoik & Co LLP, the Valuer and pending their response to the clarifications and explanations sought from them.11 Apr · Board meeting
To consider inter-alia, seeking approval of shareholders of the Company through Postal Ballot, for the voluntary delisting proposed by AstraZeneca Pharmaceuticals AB Sweden, Promoter of the Company, in terms of Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009.
Mar 2014
5 Mar · Board meeting
Board of Directors met on March 05, 2014 to consider the Delisting Proposal. After discussion, it was decided to seek additional information from the Promoter - AstraZeneca Pharmaceuticals AB, Sweden (AZP AB). Pending receipt of such additional information, consideration of the Promoter's letter dated March 01, 2014 was deferred.3 Mar · Board meeting
To consider the Delisting Proposal and Matters incidental hereto.
Jan 2014
8 Jan · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2013.
Oct 2013
9 Oct · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2013.
Jul 2013
23 Jul · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2013.
May 2013
22 May · Board meeting
Board of Directors of the Company at its meeting held on May 21, 2013 has transacted the following :(1) Recommendation of Dividend: In view of absence of profits for the year ended March 31, 2013, and to conserve resources for future growth, the Board has not recommended any dividend on equity shares for the Financial Year ended March 31, 2013.13 May · Board meeting
Inter alia, to consider and approve the Audited Financial Results of the Company, for the last quarter and financial year ended March 31, 2013.6 May · Board meeting
3 May · Board meeting
To consider the 'Strategy Plan' for the Company.3 May · Board meeting
Board of Directors of the Company at its meeting held on May 02, 2013, has noted the resignation of Mr. Luigi Felice La Corte, Director, with effect from April 15, 2013. Further, Mr. Justin Ooi has been appointed as a Director of the Company in the vacancy caused by the resignation of Mr. Luigi Felice La Corte. The Board of Directors has also approved the appointment of Mr. Sanjay Murdeshwar as an Additional Director and also as Managing Director of the Company for a period of 3 years with effect from May 02, 2013. The appointment of Mr. Sanjay Murdeshwar as Managing Director is subject to the approval of the Central Government under Part I of Schedule XIII to the Companies Act, 1956. In view of inadequacy of profits of the Company for the year ended March 31, 2013, the remuneration payable by the Company to the Managing Director has been approved by the Remuneration Committee of the Board at its meeting held after the conclusion of the Board Meeting, as well as the appointment and remuneration is subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting in accordance with the applicable provisions of Schedule XIII to the said act.
Jan 2013
23 Jan · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 2012.
Dec 2012
6 Dec · Board meeting
Board of Directors of the Company at its meeting held on December 06, 2012, inter alia, has approved the following : (1) Appointment of Mr. Narayan K. Seshadri as an Additional Director on the Board with immediate effect and he would be acting as an Independent Director; (2) The employment term of Mr. Jonathan Hunt, Interim COO & President of the Company, whose appointment had been intimated vide letter dated August 23, 2012 and was valid till December 31, 2012, has been extended till March 12, 2013.
Oct 2012
19 Oct · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2012.
Jul 2012
26 Jul · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended June 30, 2012.
May 2012
12 May · Board meeting
Board of Directors of the Company at its meeting held on May 11, 2012 has appointed Mr. Pawan Singhal as the Vice President - Legal & Secretarial of the Company, and designated him as the "Compliance Officer" of the Company.
Apr 2012
24 Apr · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended March 31, 2012.
Jan 2012
13 Jan · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended December 31, 2011.
Oct 2011
12 Oct · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter and half year ended September 30, 2011.
Jul 2011
14 Jul · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended June 30, 2011.
Jun 2011
10 Jun · Board meeting
Inter alia to consider and approve the proposal of straightening of land boundaries of factory with IDL Industries Limited.
Apr 2011
19 Apr · Board meeting
Inter alia to consider and approve the Audited Financial Results of the Company for the quarter and financial year (15 Months) ended March 31, 2011 and to recommend dividend, if any.
Jan 2011
17 Jan · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended December 31, 2010.
Oct 2010
8 Oct · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended September 30, 2010.
Jul 2010
27 Jul · Board meeting
Board at its meeting held on July 27, 2010, has given its approval for seeking the consent/approval of the Shareholders of the Company through postal ballot to the delisting proposal initiated by AstraZeneca Pharmaceuticals, AB, Sweden, promoter of the Company, pursuant to and in accordance with Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009.13 Jul · Board meeting
Board of Directors at the meeting held on July 09, 2010, considered inter-alia seeking approval of Shareholders of the Company through postal ballot, pursuant to Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009, in connection with the delisting proposal initiated by AstraZeneca Pharmaceuticals AB, Sweden, promoter of the Company. After discussions, the Board deferred the decision on the same to the next meeting of the Board of Directors, the date of which will be intimated in due course.